-
1دورية أكاديمية
المؤلفون: Jacobse, Judy N., Duane, Frances K., Boekel, Naomi B., Schaapveld, Michael, Hauptmann, Michael, Hooning, Maartje J., Seynaeve, Caroline M., Baaijens, Margreet H. A., Gietema, Jourik A., Darby, Sarah C., van Leeuwen, Flora E., Aleman, Berthe M. P., Taylor, Carolyn W.
المصدر: Jacobse , J N , Duane , F K , Boekel , N B , Schaapveld , M , Hauptmann , M , Hooning , M J , Seynaeve , C M , Baaijens , M H A , Gietema , J A , Darby , S C , van Leeuwen , F E , Aleman , B M P & Taylor , C W 2019 , ' Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors ' , International Journal of Radiation Oncology Biology Physics , vol. 103 , no. 3 , pp. 595-604 . https://doi.org/10.1016/j.ijrobp.2018.10.025Test
مصطلحات موضوعية: CARDIOVASCULAR-DISEASE, HEART-DISEASE, FOLLOW-UP, RADIOTHERAPY, THERAPY, WOMEN, RECURRENCE, MORTALITY, TOXICITY, SURGERY
الوصف: Purpose: Previous reports suggest that radiation therapy for breast cancer (BC) can cause ischemic heart disease, with the radiation-related risk increasing linearly with mean whole heart dose (MWHD). This study aimed to validate these findings in younger BC patients and to investigate additional risk factors for radiation-related myocardial infarction (MI). Methods and Materials: A nested case-control study was conducted within a cohort of BC survivors treated during 1970 to 2009. Cases were 183 patients with MI as their first heart disease after BC. One control per case was selected and matched on age and BC diagnosis date. Information on treatment and cardiovascular risk factors was abstracted from medical and radiation charts. Cardiac doses were estimated for each woman by reconstructing her regimen using modern 3-dimensional computed tomography planning on a typical patient computed tomography scan. Results: Median age at BC of cases and controls was 50.2 years (interquartile range, 45.7-54.7). Median time to MI was 13.6 years (interquartile range, 9.9-18.1). Median MWHD was 8.9 Gy (range, 0.3-35.2 Gy). MI rate increased linearly with increasing MWHD (excess rate ratio [ERR] per Gy, 6.4%; 95% confidence interval, 1.3.0%). Patients receiving >= 20 Gy MWHD had a 3.4-fold (95% confidence interval, 1.5-7.6) higher MI rate than unirradiated patients. ERRs were higher for younger women, with borderline significance (ERR<45years, 24.2%/Gy; ERR >= 50years, 2.5%/ Gy; P-interaction = .054). Whole heart dose-volume parameters did not modify the dose-response relationship significantly. Conclusions: MI rate after radiation for BC increases linearly with MWHD. Reductions in MWHD are expected to contribute to better cardiovascular health of BC survivors. (C) 2018 Elsevier Inc. All rights reserved.
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1016/j.ijrobp.2018.10.025Test
https://hdl.handle.net/11370/601f3c00-324c-4814-9c54-68b27fd7faa1Test
https://research.rug.nl/en/publications/601f3c00-324c-4814-9c54-68b27fd7faa1Test
https://pure.rug.nl/ws/files/77296113/1_s2.0_S0360301618339142_main.pdfTest -
2دورية أكاديمية
المؤلفون: Boekel, Naomi B., Jacobse, Judy N., Schaapveld, Michael, Hooning, Maartje J., Gietema, Jourik A., Duane, Frances K., Taylor, Carolyn W., Darby, Sarah C., Hauptmann, Michael, Seynaeve, Caroline M., Baaijens, Margreet H. A., Sonke, Gabe S., Rutgers, Emiel J. T., Russell, Nicola S., Aleman, Berthe M. P., van Leeuwen, Flora E.
المصدر: Boekel , N B , Jacobse , J N , Schaapveld , M , Hooning , M J , Gietema , J A , Duane , F K , Taylor , C W , Darby , S C , Hauptmann , M , Seynaeve , C M , Baaijens , M H A , Sonke , G S , Rutgers , E J T , Russell , N S , Aleman , B M P & van Leeuwen , F E 2018 , ' Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer ' ....
مصطلحات موضوعية: PLUS ADJUVANT CHEMOTHERAPY, CONGESTIVE-HEART-FAILURE, POPULATION-BASED COHORT, FOLLOW-UP, RANDOMIZED-TRIALS, HODGKIN LYMPHOMA, RADIATION-THERAPY, NSABP B-31, RISK, RADIOTHERAPY
الوصف: BACKGROUND: Improved breast cancer (BC) survival and evidence showing beneficial effects of internal mammary chain (IMC) irradiation underscore the importance of studying late cardiovascular effects of BC treatment. METHODS: We assessed cardiovascular disease (CVD) incidence in 14,645 Dutch BC patients aged <62 years, treated during 1970-2009. Analyses included proportional hazards models and general population comparisons. RESULTS: CVD rate-ratio for left-versus-right breast irradiation without IMC was 1.11 (95% CI 0.93-1.32). Compared to right-sided breast irradiation only, IMC irradiation (interquartile range mean heart doses 9-17 Gy) was associated with increases in CVD rate overall, ischaemic heart disease (IHD), heart failure (HF) and valvular heart disease (hazard ratios (HRs): 1.6-2.4). IHD risk remained increased until at least 20 years after treatment. Anthracycline-based chemotherapy was associated with an increased HF rate (HR = 4.18, 95% CI 3.07-5.69), emerging <5 years and remaining increased at least 10-15 years after treatment. IMC irradiation combined with anthracycline-based chemotherapy was associated with substantially increased HF rate (HR = 9.23 95% CI 6.01-14.18), compared to neither IMC irradiation nor anthracycline-based chemotherapy. CONCLUSIONS: Women treated with anthracycline-based chemotherapy and IMC irradiation (in an older era) with considerable mean heart dose exposure have substantially increased incidence of several CVDs. Screening may be appropriate for some BC patient groups.
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1038/s41416-018-0159-xTest
https://hdl.handle.net/11370/7317e120-604d-4468-b746-21b480f85e6eTest
https://research.rug.nl/en/publications/7317e120-604d-4468-b746-21b480f85e6eTest
https://pure.rug.nl/ws/files/74424437/s41416_018_0159_x.pdfTest -
3دورية أكاديمية
المؤلفون: Vos, Elvira L., Siesling, Sabine, Baaijens, Margreet H. A., Verhoef, Cornelis, Jager, Agnes, Voogd, Adri C., Koppert, Linetta B.
المصدر: Vos , E L , Siesling , S , Baaijens , M H A , Verhoef , C , Jager , A , Voogd , A C & Koppert , L B 2017 , ' Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival ' , Breast Cancer Research and Treatment , vol. 164 , no. 1 , pp. 157-167 . https://doi.org/10.1007/s10549-017-4232-6Test
مصطلحات موضوعية: Breast-conserving surgery, Resection margins, Re-excision, Re-operation, Ipsilateral breast tumor recurrence, Disease-free survival, Overall survival, POPULATION-BASED COHORT, NO BOOST TRIAL, LOCAL RECURRENCE, RADIATION-THERAPY, CONSENSUS GUIDELINE, SURGICAL MARGINS, EORTC BOOST, FOLLOW-UP, CANCER, IRRADIATION
الإتاحة: https://doi.org/10.1007/s10549-017-4232-6Test
https://cris.maastrichtuniversity.nl/en/publications/118f7436-64c6-4041-82a9-59affaadc2b7Test -
4دورية أكاديمية
المؤلفون: Doebar, Shusma C., van den Broek, Esther C., Koppert, Linetta B., Jager, Agnes, Baaijens, Margreet. H. A., Obdeijn, Inge-Marie A. M., van Deurzen, Carolien H. M.
المصدر: Breast Cancer Research and Treatment ; volume 158, issue 1, page 179-187 ; ISSN 0167-6806 1573-7217
مصطلحات موضوعية: Cancer Research, Oncology
-
5دورية أكاديمية
المؤلفون: Jacobse, Judy N., Schaapveld, Michael, Boekel, Naomi B., Hooning, Maartje J., Jager, Agnes, Baaijens, Margreet H. A., Hauptmann, Michael, Russell, Nicola S., Rutgers, Emiel J. T., Aleman, Berthe M. P., Sonke, Gabe S., van Leeuwen, Flora E.
المساهمون: KWF Kankerbestrijding
المصدر: Breast Cancer Research and Treatment ; volume 185, issue 1, page 205-214 ; ISSN 0167-6806 1573-7217
مصطلحات موضوعية: Cancer Research, Oncology
-
6دورية أكاديمية
المؤلفون: De Bruin, Marie L, Sparidans, Judith, van't Veer, Mars B, Noordijk, Evert M, Louwman, Marieke W J, Zijlstra, Josée M, van den Berg, Hendrik, Russell, Nicola S, Broeks, Annegien, Baaijens, Margreet H A, Aleman, Berthe M P, van Leeuwen, Flora E
المساهمون: Sub Pharmacoepidemiology, Pharmacoepidemiology and Clinical Pharmacology
مصطلحات موضوعية: Adult, Breast Neoplasms, Dose-Response Relationship, Radiation, Female, Follow-Up Studies, Hodgkin Disease, Humans, Incidence, Middle Aged, Multivariate Analysis, Neoplasms, Second Primary, Netherlands, Outcome Assessment (Health Care), Proportional Hazards Models, Radiotherapy, Radiotherapy Dosage, Risk Factors, Survival Analysis, Survivors, Young Adult
الوصف: PURPOSE: We assessed the long-term risk of breast cancer (BC) after treatment for Hodgkin's lymphoma (HL). We focused on the volume of breast tissue exposed to radiation and the influence of gonadotoxic chemotherapy (CT). PATIENTS AND METHODS: We performed a cohort study among 1,122 female 5-year survivors treated for HL before the age of 51 years between 1965 and 1995. We compared the incidence of BC with that in the general population. To assess the risk according to radiation volume and hormone factors, we performed multivariate Cox regression analyses. RESULTS: After a median follow-up of 17.8 years, 120 women developed BC (standardized incidence ratio [SIR], 5.6; 95% CI, 4.6 to 6.8), absolute excess risk 57 per 10,000 patients per year. The overall cumulative incidence 30 years after treatment was 19% (95% CI, 16% to 23%); for those treated before age 21 years, it was 26% (95% CI, 19% to 33%). The relative risk remained high after prolonged follow-up (> 30 years after treatment: SIR, 9.5; 95% CI, 4.9 to 16.6). Mantle field irradiation (involving the axillary, mediastinal, and neck nodes) was associated with a 2.7-fold increased risk (95% CI, 1.1 to 6.9) compared with similarly dosed (36 to 44 Gy) mediastinal irradiation alone. Women with >or= 20 years of intact ovarian function after radiotherapy at young ages (< 31 years) experienced significantly higher risks for BC than those with fewer than 10 years of intact ovarian function. CONCLUSION: Reduction of radiation volume appears to decrease the risk for BC after HL. In addition, shorter duration of intact ovarian function after irradiation is associated with a significant reduction of the risk for BC.
وصف الملف: image/pdf
-
7دورية أكاديمية
المؤلفون: Jacobse, Judy N., Schaapveld, Michael, Boekel, Naomi B., Hooning, Maartje J., Jager, Agnes, Baaijens, Margreet H. A., Hauptmann, Michael, Russell, Nicola S., Rutgers, Emiel J. T., Aleman, Berthe M. P., Sonke, Gabe S., van Leeuwen, Flora E.
المصدر: Breast Cancer Research & Treatment; 2021, Vol. 185 Issue 1, p205-214, 10p
مستخلص: Purpose: Anthracyclines and trastuzumab can increase the risk of heart failure (HF), but long-term cardiotoxicity data in breast cancer (BC) patients treated at younger ages are limited. Furthermore, it is unknown whether aromatase inhibitors are associated with HF risk. Methods: HF risk was studied in a multicenter cohort of BC survivors treated during 2000–2009, at age < 61 years. Information on treatment and cardiovascular disease incidence was collected through medical records, general practitioners and cardiologists. Analyses included multivariable Cox regression and cumulative incidence curves. Results: In total, 10,209 women with a median age at BC diagnosis of 50.3 years and a median follow-up of 8.9 years were enrolled in the study. Anthracycline-based chemotherapy was associated with HF (hazard ratio [HR] 2.18, 95% confidence interval [CI] 1.41–3.39) and risk increased with increasing cumulative anthracycline dose. For trastuzumab, HF risk was highest within the first 2 years after treatment (HR
0–2 years : 13.06, 95% CI 5.70–29.92) and decreased thereafter (HR2–4 years : 4.84, 95% CI 1.99–11.75 and HR≥4 years : 0.64, 95% CI 0.23–1.81). The 10-year cumulative incidence of HF was 4.8% (95% CI 3.2–6.8) among patients treated with anthracyclines and trastuzumab. One-third of patients who developed HF after trastuzumab had long-term impaired cardiac function. Patients treated with aromatase inhibitors alone also had higher HF risk (HR 2.18, 95% CI 1.24–3.82) compared to patients not receiving endocrine therapy. Conclusions: Our results stress the importance of considering anthracycline-free regimens in BC patients who need trastuzumab-containing treatment. The association between aromatase inhibitors and HF needs confirmation. [ABSTRACT FROM AUTHOR]: Copyright of Breast Cancer Research & Treatment is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
-
8دورية أكاديمية
المؤلفون: Boekel, Naomi B, Jacobse, Judy N, Schaapveld, Michael, Hooning, Maartje J, Gietema, Jourik A, Duane, Frances K, Taylor, Carolyn W, Darby, Sarah C, Hauptmann, Michael, Seynaeve, Caroline M, Baaijens, Margreet H A, Sonke, Gabe S, Rutgers, Emiel J T, Russell, Nicola S, Aleman, Berthe M P, van Leeuwen, Flora E
المصدر: British Journal of Cancer; Aug2018, Vol. 119 Issue 4, p408-418, 11p
مستخلص:
Background: Improved breast cancer (BC) survival and evidence showing beneficial effects of internal mammary chain (IMC) irradiation underscore the importance of studying late cardiovascular effects of BC treatment.Methods: We assessed cardiovascular disease (CVD) incidence in 14,645 Dutch BC patients aged <62 years, treated during 1970-2009. Analyses included proportional hazards models and general population comparisons.Results: CVD rate-ratio for left-versus-right breast irradiation without IMC was 1.11 (95% CI 0.93-1.32). Compared to right-sided breast irradiation only, IMC irradiation (interquartile range mean heart doses 9-17 Gy) was associated with increases in CVD rate overall, ischaemic heart disease (IHD), heart failure (HF) and valvular heart disease (hazard ratios (HRs): 1.6-2.4). IHD risk remained increased until at least 20 years after treatment. Anthracycline-based chemotherapy was associated with an increased HF rate (HR = 4.18, 95% CI 3.07-5.69), emerging <5 years and remaining increased at least 10-15 years after treatment. IMC irradiation combined with anthracycline-based chemotherapy was associated with substantially increased HF rate (HR = 9.23 95% CI 6.01-14.18), compared to neither IMC irradiation nor anthracycline-based chemotherapy.Conclusions: Women treated with anthracycline-based chemotherapy and IMC irradiation (in an older era) with considerable mean heart dose exposure have substantially increased incidence of several CVDs. Screening may be appropriate for some BC patient groups. [ABSTRACT FROM AUTHOR]: Copyright of British Journal of Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
-
9دورية أكاديمية
المؤلفون: Litiere, Saskia, Werutsky, Gustavo, Fentiman, Ian, Rutgers, Emiel, Christiaens, Marie-Rose, Van Limbergen, Erik, Baaijens, Margreet H. A., Bogaerts, Jan, Bartelink, Harry
المصدر: Litiere , S , Werutsky , G , Fentiman , I , Rutgers , E , Christiaens , M-R , Van Limbergen , E , Baaijens , M H A , Bogaerts , J & Bartelink , H 2012 , ' Breast conserving therapy versus mastectomy for stage I-II breast cancer : 20 year follow-up of the EORTC 10801 phase 3 randomised trial ' , The Lancet Oncology , vol. 13 , no. 4 , pp. 412-419 . https://doi.org/10.1016/S1470-2045Test(12)70042-6
مصطلحات موضوعية: CLINICAL-PRACTICE GUIDELINES, COMPARING TOTAL MASTECTOMY, RADICAL-MASTECTOMY, LOCAL RECURRENCE, POSTMASTECTOMY RADIOTHERAPY, RADIATION-THERAPY, CONSERVATION, SURVIVAL, SURGERY, RISK
الوصف: Background The EORTC 10801 trial compared breast-conserving therapy (BCT) with modified radical mastectomy (MRM) in patients with tumours 5 cm or smaller and axillary node negative or positive disease. Compared with BCT, MRM resulted in better local control, but did not affect overall survival or time to distant metastases. We report 20-year follow-up results. Methods The EORTC 10801 trial was open for accrual between 1980 and 1986 in eight centres in the UK, the Netherlands, Belgium, and South Africa. 448 patients were randomised to BCT and 420 to MRM. Randomisation was done centrally, stratifying patients by institute, carcinoma stage (I or II), and menopausal status. BCT comprised of lumpectomy and complete axillary clearance, followed by breast radiotherapy and a tumour-bed boost. The primary endpoint was time to distant metastasis. This analysis was done on all eligible patients, as they were randomised. Findings After a median follow-up of 22 . 1 years (IQR 18 . 5-23 . 8), 175 patients (42%) had distant metastases in the MRM group versus 207 (46%) in the BCT group. Furthermore, 506 patients (58%) died (232 [55%] in the MRM group and 274 [61%] in the BCT group). No significant difference was observed between BCT and MRM for time to distant metastases (hazard ratio 1 . 13, 95% CI 0 . 92-1 . 38; p=0 . 23) or for time to death (1 . 11, 0 . 94-1 . 33; 0 . 23). Cumulative incidence of distant metastases at 20 years was 42 . 6% (95% CI 37 . 8-47 . 5) in the MRM group and 46 . 9% (42 . 2-51 . 6) in the BCT group. 20-year overall survival was estimated to be 44 . 5% (95% CI 39 . 3-49 . 5) in the MRM group and 39 . 1% (34 . 4-43 . 9) in the BCT group. There was no difference between the groups in time to distant metastases or overall survival by age (time to distant metastases: Interpretation BCT, including radiotherapy, offered as standard care to patients with early breast cancer seems to be justified, since long-term follow-up in this trial showed similar survival to that after mastectomy.
الإتاحة: https://doi.org/10.1016/S1470-2045Test(12)70042-6
https://kclpure.kcl.ac.uk/portal/en/publications/f8ecaaf2-1663-4e3a-a2ee-a2e238330c18Test -
10دورية أكاديمية
المؤلفون: Aleman, Berthe M P, Raemaekers, John M M, Tomiŝiĉ, Radka, Baaijens, Margreet H A, Bortolus, Roberto, Lybeert, Marnix L M, van der Maazen, Richard W M, Girinsky, Théodore, Demeestere, Geertrui, Lugtenburg, Pieternella, Lievens, Yolande, de Jong, Daphne, Pinna, Antonella, Henry-Amar, Michel
مصطلحات موضوعية: Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Combined Modality Therapy, Disease-Free Survival, Doxorubicin, Female, Hodgkin Disease, Humans, Logistic Models, Male, Mechlorethamine, Mediastinal Neoplasms, Middle Aged, Neoplasms, Second Primary, Prednisone, Procarbazine, Remission Induction, Survival Rate, Vinblastine, Vincristine
الوصف: PURPOSE: The use of radiotherapy in patients with advanced Hodgkin's lymphoma (HL) is controversial. The purpose of this study was to describe the role of radiotherapy in patients with advanced HL who were in partial remission (PR) after chemotherapy. METHODS: In a prospective randomized trial, patients <70 years old with previously untreated Stage III-IV HL were treated with six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycine, vinblastine hybrid chemotherapy. Patients in complete remission (CR) after chemotherapy were randomized between no further treatment and involved-field radiotherapy (IF-RT). Those in PR after six cycles received IF-RT (30 Gy to originally involved nodal areas and 18-24 Gy to extranodal sites with or without a boost). RESULTS: Of 739 enrolled patients, 57% were in CR and 33% in PR after chemotherapy. The median follow-up was 7.8 years. Patients in PR had bulky mediastinal involvement significantly more often than did those in CR after chemotherapy. The 8-year event-free survival and overall survival rate for the 227 patients in PR who received IF-RT was 76% and 84%, respectively. These rates were not significantly different from those for CR patients who received IF-RT (73% and 78%) or for those in CR who did not receive IF-RT (77% and 85%). The incidence of second malignancies in patients in PR who were treated with IF-RT was similar to that in nonirradiated patients. CONCLUSION: Patients in PR after six cycles of mechlorethamine, vincristine, procarbazine, prednisone/doxorubicine, bleomycine, vinblastine treated with IF-RT had 8-year event-free survival and overall survival rates similar to those of patients in CR, suggesting a definite role for RT in these patients. ; status: published
العلاقة: International journal of radiation oncology, biology, physics vol:67 issue:1 pages:19-30; https://lirias.kuleuven.be/handle/123456789/34696Test; http://linkinghub.elsevier.com/retrieve/pii/S0360-3016Test(06)02813-6
النص الكامل